|
2022 Conference Publication PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of <SUP>177</SUP>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)Buteau, James Patrick, Martin, Andrew James, Emmett, Louise, Iravani, Amir, Sandhu, Shahneen Kaur, Joshua, Anthony M., Zhang, Alison Yan, Francis, Roslyn J., Scott, Andrew Mark, Azad, Arun, McJannett, Margaret Mary, Stockler, Martin R., Williams, Scott, Davis, Ian D. and Hofman, Michael S. (2022). PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). ASCO Genitourinary Cancers Symposium, Electr Network, Feb 17-19, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.010 |
|
2022 Conference Publication SUB-urothelial durvalumab injection: 1 (SUBDUE-1)-Results from the first nine urothelial cancer patients using a dose-escalation scheduleHayne, Dickon, Swarbrick, Nicole, McCombie, Stephen, Moe, Andrew, Hawks, Cynthia, Viswambaram, Pravin, Conduit, Ciara, Liow, Elizabeth Chien Hern, Spalding, Lisa, Bothe, Jarrad, Ferguson, Tom, Martin, Andrew James, Davis, Ian D. and Redfern, Andrew David (2022). SUB-urothelial durvalumab injection: 1 (SUBDUE-1)-Results from the first nine urothelial cancer patients using a dose-escalation schedule. ASCO Genitourinary Cancers Symposium, Electr Network, Feb 17-19, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.483 |
|
2022 Conference Publication ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)Emmett, Louise, Subramaniam, Shalini, Martin, Andrew James, Zhang, Alison Yan, Yip, Sonia, Crumbaker, Megan, Rana, Nisha, Francis, Roslyn J., Hofman, Michael S., Joshua, Anthony M., Sandhu, Shahneen Kaur, Azad, Arun, Gedye, Craig, Weickhardt, Andrew James, Goh, Jeffrey C., Ng, Siobhan, Voskoboynik, Mark, McJannett, Margaret Mary, Stockler, Martin R. and Davis, Ian D. (2022). ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). ASCO Genitourinary Cancers Symposium, Electr Network, Feb 17-19, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.TPS205 |
|
2022 Conference Publication INTEGRATE IIb: A randomized phase III open label study of regorafenib plus nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC)Pavlakis, Nick, Shitara, Kohei, Sjoquist, Katrin Marie, Martin, Andrew James, Jaworski, Anthony, Yip, Sonia, Oh, Do-Youn, Moehler, Markus H., Bekaii-Saab, Tanios S., Simes, John and Goldstein, David (2022). INTEGRATE IIb: A randomized phase III open label study of regorafenib plus nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC). ASCO Gastrointestinal Cancers Symposium, San Francisco Ca, Jan 20-22, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.4_suppl.TPS366 |
|
2020 Conference Publication DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiationNiazi, T., Williams, S., Davis, I. D., Stockler, M. R., Martin, A., Bracken, K., Roncolato, F., McJannett, M., Horvath, L., Sengupta, S., Hughes, S., McDermott, R., Catto, J., Kelly, P., Vapiwala, N., Parulekar, W. R., Morgan, S., Rendon, R. A. and Sweeney, C. (2020). DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. ESMO Virtual Congress, Electr Network, Sep 19-Oct 18, 2020. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2020.08.2088 |
|
2020 Conference Publication P3BEP (ANZUP 1302): an international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs)Subramaniam, Shalini, Toner, Guy C., Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Frazier, A. Lindsay, Mazhar, Danish, Ford, Kate, Walpole, Euan Thomas, Stevanovic, Amanda Gwendolyn, Wyld, David, Troon, Simon, Hanning, Fritha J., Birtle, Alison Jane, Wheater, Matthew James, Huddart, Robert A., White, Jeff D., Spunt, Sheri L. and Grimison, Peter S. (2020). P3BEP (ANZUP 1302): an international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs). Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San Francisco, CA USA, 13-15 February 2020. Alexandria, VA: American Society of Clinical Oncology. |
|
2017 Conference Publication The Chest Australia Trial: A Phase II Randomised Controlled Trial of an Intervention to Reduce Time to Consult with Symptoms of Lung CancerEmery, Jon, Murray, Sonya, Campbell, Neil, Walter, Fiiona M., Mazza, Danielle, Habgood, Emily, Kutzer, Yvonne, Martin, Andrew, Goodall, Stephen, Barnes, David and Murchie, Peter (2017). The Chest Australia Trial: A Phase II Randomised Controlled Trial of an Intervention to Reduce Time to Consult with Symptoms of Lung Cancer. HOBOKEN: WILEY. |
|
2017 Conference Publication Predicting Chemotherapy Toxicity in Older Adults: Comparing the Value of the Carg Toxicity Score With Oncologists' Estimates of ToxicityMoth, Erin B., Kiely, Belinda E., Naganathan, Vasikaran, Martin, Andrew, Stefanic, Natalie, Beale, Philip, Grimison, Peter and Blinman, Prunella (2017). Predicting Chemotherapy Toxicity in Older Adults: Comparing the Value of the Carg Toxicity Score With Oncologists' Estimates of Toxicity. HOBOKEN: WILEY. |
|
2017 Conference Publication Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in A Randomised Phase II Trial of Regorafenib in Advanced Gastric CancerVasista, Anuradha, Martin, Andrew, Pavlakis, Nick, Sjoquist, Katrin M., Snow, Stephanie, Jonker, Derek, Chua, Yu Jo, Epstein, Richard, Bonaventura, Tony, Khasraw, Mustafa, Varma, Suresh, Singhal, Nimit, Ransom, David, Aubin, Francine, Burkes, Ronald, Lim, Howard, Lemay, Frederic, Begbie, Stephen, Stockler, Martin and Kiely, Belinda (2017). Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in A Randomised Phase II Trial of Regorafenib in Advanced Gastric Cancer. HOBOKEN: WILEY. |
|
2017 Conference Publication Can Time to Progression on Last Line Treatment Inform us About Post-Progression Survival Time in Advanced Gastric Cancer?Vasista, Anuradha, Martin, Andrew, Pavlakis, Nick, Sjoquist, Katrin M., Goldstein, David, Shapiro, Jeremy, Karapetis, Chris, Gill, Sanjeev, Jain, Vikram, Liu, Geoffrey, Kannourakis, George, Kim, Yeul Hong, Wigston (Nott), Louise, Snow, Stephanie, Harris, Dean, Jonker, Derek, Chua, Yu Jo, Stockler, Martin and Kiely, Belinda (2017). Can Time to Progression on Last Line Treatment Inform us About Post-Progression Survival Time in Advanced Gastric Cancer?. HOBOKEN: WILEY. |
|
2017 Conference Publication Physical Activity for Women with Metastatic Breast Cancer: A Pilot RCTYee, Jasmine, Davis, Glen M., Hackett, Daniel, Beith, Janem M., Wilcken, Nicholas, Currow, David, Emery, Jon, Phillips, Jane, Martin, Andrew, Hui, Rina, Harrison, Michelle, Segelov, Eva and Kilbreath, Sharon L. (2017). Physical Activity for Women with Metastatic Breast Cancer: A Pilot RCT. HOBOKEN: WILEY. |
|
2017 Conference Publication P3BEP (ANZUP 1302): An International Randomised Phase III Trial of Accelerated Versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients With Intermediate and Poor-Risk Metastatic Germ Cell Tumours (GCTS)Wong, Nicole, Nayar, Namrata, Lawrence, Nicola, Stockler, Martin, Martin, Andrew, Yip, Sonia, Yeung, Annie, Friedlander, Michael, Mazhar, Danish, Pashankar, Farzana, Quinn, David, Walker, Roderick, Winstanley, Mark, Weickhardt, Andrew, Hanning, Fritha, Stevanovic, Amanda, Davis, Ian, Toner, Guy and Grimison, Peter (2017). P3BEP (ANZUP 1302): An International Randomised Phase III Trial of Accelerated Versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients With Intermediate and Poor-Risk Metastatic Germ Cell Tumours (GCTS). HOBOKEN: WILEY. |
|
2017 Conference Publication Predicted benefits of adjuvant sorafenib after nephrectomy for renal cell carcinoma (RCC) in SORCE: an international, placebo-controlled, randomised phase 3 trialLawrence, N. J., Martin, A., Davis, I. D., Troon, S., Sengupta, S., Hovey, E. J., Coskinas, X., Kaplan, R., Ritchie, A. W. S., Meade, A., Eisen, T., Blinman, P. and Stockler, M. R. (2017). Predicted benefits of adjuvant sorafenib after nephrectomy for renal cell carcinoma (RCC) in SORCE: an international, placebo-controlled, randomised phase 3 trial. 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS. |
|
2017 Conference Publication Accuracy and prognostic significance of oncologists' estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancerVasista, A., Martin, A., Pavlakis, N., Sjoquist, K., Snow, S., Jonker, D., Chua, Y. J., Epstein, R., Bonaventura, A., Khasraw, M., Varma, S. C., Singhal, N., Ransom, D. T., Aubin, F., Burkes, R., Lim, H., Lemay, F., Begbie, S., Stockler, M. R. and Kiely, B. (2017). Accuracy and prognostic significance of oncologists' estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer. 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS. |
|
2017 Conference Publication Predicted Benefits of Adjuvant Sorafenib After Nephrectomy for Renal Cell Carcinoma (RCC) in SORCE: An International, Placebo-Controlled, Randomized Phase 3 TrialLawrence, N., Martin, A., Davis, I. D., Troon, S., Sengupta, S., Hovey, E., Coskinas, X., Kaplan, R., Ritchie, A., Meade, A., Eisen, T., Blinman, P. and Stockler, M. (2017). Predicted Benefits of Adjuvant Sorafenib After Nephrectomy for Renal Cell Carcinoma (RCC) in SORCE: An International, Placebo-Controlled, Randomized Phase 3 Trial. HOBOKEN: WILEY. |
|
2017 Conference Publication USING TRIAL INFRASTRUCTURE EFFICIENTLY: PLATFORM, FACTORIAL, AND UMBRELLA TRIAL DESIGNSMartin, Andrew (2017). USING TRIAL INFRASTRUCTURE EFFICIENTLY: PLATFORM, FACTORIAL, AND UMBRELLA TRIAL DESIGNS. HOBOKEN: WILEY. |
|
2016 Conference Publication Are Multiple Interventions Needed To Influence Physician Prescribing Behaviour: Implications For The Future?Truter, Ilse, Godman, Brian, Baker, Amanj, Bucsics, Anna, Fadare, Joseph, Hesse, Ulrik, Martin, Andrew, Kwon, Hye Young, Zara, Corinne and Bennie, Marion (2016). Are Multiple Interventions Needed To Influence Physician Prescribing Behaviour: Implications For The Future?. HOBOKEN: WILEY-BLACKWELL. |
|
2016 Conference Publication A PROSPECTIVE, LONGITUDINAL COHORT STUDY TO INVESTIGATE THE IMPACT OF CHEMOTHERAPY ON COGNITION IN TESTICULAR CANCERStockler, Martin, Whitford, Hayley S., Kalinowski, Pawel, Schembri, Adrian, Toner, Guy, Grimison, Peter, Martin, Andrew, Davis, Ian, Wong, Nicole and Olver, Ian (2016). A PROSPECTIVE, LONGITUDINAL COHORT STUDY TO INVESTIGATE THE IMPACT OF CHEMOTHERAPY ON COGNITION IN TESTICULAR CANCER. HOBOKEN: WILEY-BLACKWELL. |
|
2016 Conference Publication LONG-TERM OUTCOMES OF ACCELERATED BEP (BLEOMYCIN, ETOPOSIDE, CISPLATIN) FOR ADVANCED GERM-CELL TUMORS: UPDATED ANALYSIS OF AN AUSTRALIAN MULTICENTER PHASE II TRIALLawrence, Nicola, Martin, Andrew, Toner, Guy, Stockler, Martin, Buizen, Luke, Thomson, Damien, Gebski, Val, Friedlander, Michael, Yeung, Annie, Gurney, Howard, Rosenthal, Mark, Singhal, Nimit, Kichenadasse, Ganessan, Wong, Shirley, Lewis, Craig, Vasey, Paul and Grimison, Peter (2016). LONG-TERM OUTCOMES OF ACCELERATED BEP (BLEOMYCIN, ETOPOSIDE, CISPLATIN) FOR ADVANCED GERM-CELL TUMORS: UPDATED ANALYSIS OF AN AUSTRALIAN MULTICENTER PHASE II TRIAL. HOBOKEN: WILEY-BLACKWELL. |
|
2016 Conference Publication Permanently grafted abrasion resistant nanocomposites for anti-icing applicationsGao, Jing, Martin, Andrew, Yatvin, Jeremy and Locklin, Jason (2016). Permanently grafted abrasion resistant nanocomposites for anti-icing applications. WASHINGTON: AMER CHEMICAL SOC. |
